Anti-Bad (phospho S112) antibody [EPR1891(2)]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(25 Publications)
Rabbit Recombinant Monoclonal BAD phospho S112 antibody. Suitable for IP, Dot, WB and reacts with Human, Rat, Synthetic peptide samples. Cited in 25 publications.
View Alternative Names
BBC6, BCL2L8, BAD, Bcl2-associated agonist of cell death, Bcl-2-binding component 6, Bcl-2-like protein 8, Bcl-xL/Bcl-2-associated death promoter, Bcl2 antagonist of cell death, Bcl2-L-8
- IP
Lab
Immunoprecipitation - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
ab129192 (purified) at 1/30 immunoprecipitating Bad in HeLa cell lysate treated with Calcyculin A (Lane 1). For western blotting a HRP-conjugated anti-rabbit IgG was used as the secondary antibody (1/1000).
Blocking buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM /TBST.
All lanes:
Immunoprecipitation - Anti-Bad (phospho S112) antibody [EPR1891(2)] (ab129192)
Predicted band size: 18 kDa
false
- WB
Unknown
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
All lanes:
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (ab129192) at 1/1000 dilution
Lane 1:
HeLa cell lysates, untreated at 10 µg
Lane 2:
HeLa cell lysates, treated with Calyculin A at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 18 kDa
false
- WB
Lab
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
Blocking and diluting buffer and concentration : 5% NFDM/TBST
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) 1 : 1,000,000 dilution
This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.
All lanes:
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (ab129192) at 1/1000 dilution
Lane 1:
Untreated HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate. (Untreated membrane) at 20 µg
Lane 2:
HeLa treated with 100 ng/ml Calyculin A for 30 min whole cell lysate. (Untreated membrane) at 20 µg
Lane 3:
HeLa treated with 100 ng/ml Calyculin A for 30 min whole cell lysate. (Phosphatase treated membrane) at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Observed band size: 23 kDa
true
Exposure time: 180s
- WB
Lab
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
Blocking buffer : 5% NFDM/TBST
Dilution buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (ab129192) at 1/20000 dilution
Lane 1:
Untreated HeLa cell lysate at 10 µg
Lane 2:
HeLa cell lysate treated with Calcyculin A at 10 µg
Secondary
All lanes:
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 18 kDa
Observed band size: 23 kDa
false
- WB
Lab
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
Blocking buffer : 5% NFDM/TBST
Dilution buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (ab129192) at 1/5000 dilution
Lane 1:
Untreated C6 cells at 10 µg
Lane 2:
C6 cells treated with Calcyculin A at 10 µg
Secondary
All lanes:
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 18 kDa
Observed band size: 23 kDa
false
- Dot
Lab
Dot Blot - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
Dot blot analysis of Bad (phospho S112) using ab129192 primary antibody at a dilution of 1/1000. ab97051 was used as a secondary antibody at a dilution of 1/100000.
Lane 1 : Bad (pS112) phospho peptide
Lane 2 : Bad non-phospho peptide
Blocking and diluting buffer : 5% NFDM/TBST
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-Bad (phospho S112) antibody [EPR1891(2)] (AB129192)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Its main role is to promote apoptosis by binding to anti-apoptotic proteins like Bcl-2 and Bcl-XL displacing pro-apoptotic Bax and Bak proteins to trigger cell death. Bad functions as part of the mitochondrial apoptosis pathway and is known to form complexes with phosphorylated proteins. Phosphorylation of Bad by kinases can lead to its sequestration to the cytoplasm reducing apoptosis.
Pathways
Its action is pivotal in the PI3K/Akt signaling pathway. This pathway involves growth factors and cell survival signals where phosphorylation of Bad inhibits its pro-apoptotic activity. Bad interacts with proteins like Akt and 14-3-3 to modulate cell survival. Disruption in its regulation through these pathways may lead to abnormal cell survival or death.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (25)
Recent publications for all applications. Explore the full list and refine your search
International journal of molecular sciences 26: PubMed40565356
2025
Applications
Unspecified application
Species
Unspecified reactive species
Advances in pharmacological and pharmaceutical sciences 2024:2653426 PubMed39544485
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports 42:113184 PubMed37776520
2023
Applications
Unspecified application
Species
Unspecified reactive species
Molecules (Basel, Switzerland) 28: PubMed37049702
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell death and differentiation 30:195-207 PubMed36171331
2022
Applications
Unspecified application
Species
Unspecified reactive species
Stem cells international 2022:9806887 PubMed36199627
2022
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 24:289 PubMed35928803
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 11:727605 PubMed34513705
2021
Applications
Unspecified application
Species
Unspecified reactive species
Aging 13:14219-14233 PubMed33988127
2021
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 21:486 PubMed33790995
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com